Introduction
The human genome sequence was completed in draft form in 2001 (Lander et al., 2001; Venter et al., 2001) . Shortly thereafter, the genome sequences of several model organisms were determined (Chinwalla et al., 2002; Gibbs et al., 2004; Chimpanzee Sequencing and Analysis Consortium, 2005) . These feats were accomplished with Sanger DNA sequencing, which was limited in throughput and high cost; indeed, the first human genome sequence was estimated to cost 0.5-1 billion dollars. These limitations reduced the potential of DNA sequencing for other applications, such as personal genome sequencing. Following the release of the ''finished'' human genome (International Human Genome Sequencing Consortium, 2004) , the National Human Genome Research Institute (NGHRI) created a 70 million dollar DNA sequencing technology initiative aimed at achieving a $1,000 human genome in 10 years (Schloss, 2008) , and a flurry of high-throughput sequencing (HTS) technologies emerged.
To put this initiative in perspective, improvements to traditional Sanger sequencing had decreased the per base cost by around 100-fold by the completion of the Human Genome Project (Schloss, 2008) . To reach the $1,000 dollar genome threshold, however, an additional leap of five orders of magnitude was necessary. Much of this divide has been traversed-the cost of a genome sequence (without interpretation) is presently less than $2,000. The road to this milestone involved many commercial HTS platforms, which differ in their details but typically follow a similar general paradigm: template preparation, clonal amplification, followed by cyclical rounds of massively parallel sequencing. The specific strategy employed by each platform determines the quality, quantity, and biases of the resulting sequence data and the platform's usefulness for particular applications.
Several excellent reviews have covered HTS platform strategies in great depth (Metzker, 2010; Morey et al., 2013) . Many important platforms are not covered here, including Roche/ 454's pyrophosphate Genome Sequencer (Margulies et al., 2005) and Helicos' single-molecule Heliscope sequencer (Harris et al., 2008) as well as the Polonator (Shendure et al., 2005 ), ABI's SOLiD (Valouev et al., 2008) , and Complete Genomics' DNA nano-array sequencer (Drmanac et al., 2010) . Instead, we focus on the most commonly used platforms today as well as more recent developments. We also provide an overview of the growing array of HTS applications and highlight their use by the genomics community to illuminate previously intractable topics in biology. Finally, we discuss the limitations of current platforms and challenges to clinical sequencing.
Overview of Selected Commercially Available HTS Platforms
Illumina Illumina/Solexa released the Genome Analyzer II in 2006, and advances in Illumina's technology over the intervening years have largely set the pace for the tremendous gains in output and reductions in cost ( Figure 1 ). As a consequence, Illumina machines currently dominate the HTS market. The sequencing process involves clonal amplification of adaptor-ligated DNA fragments on the surface of a glass slide (Bentley et al., 2008) ( Figure 2A ). Bases are read using a cyclic reversible termination strategy, which sequences the template strand one nucleotide at a time through progressive rounds of base incorporation, washing, imaging, and cleavage. In this strategy, fluorescently labeled 3 0 -O-azidomethyl-dNTPs are used to pause the polymerization reaction, enabling removal of unincorporated bases and fluorescent imaging to determine the added nucleotide (Guo et al., 2008) . Following scanning of the flow cell with a coupled-charge device (CCD) camera, the fluorescent moiety and the 3 0 block are removed, and the process is repeated. Across all Illumina models the overall error rates are below 1%, and the most common type of error is substitution (Dohm et al., 2008) .
Illumina currently produces a suite of sequencers (MiSeq, NextSeq 500, and the HiSeq series) optimized for a variety of throughputs and turnaround times. The MiSeq and HiSeqs are the most established platforms. The MiSeq is designed as a fast, personal benchtop sequencer, with run times as low as 4 hr and outputs intended for targeted sequencing and sequencing of small genomes. The HiSeq 2500, on the other hand, is engineered for high-throughput applications, yielding current outputs of 1 Tb in 6 days. Unlike previous HiSeq models, the HiSeq 2500 can also be run in rapid mode, which is less cost effective but can produce a 303 human genome in 27 hr.
In early 2014, Illumina introduced the NextSeq 500 as well as the HiSeq X Ten. Similar to the MiSeq, the NextSeq 500 is designed as a fast benchtop sequencer for individual labs.
However, the NextSeq is capable producing 120 Gb, or a single 303 genome, in less than 30 hr. The NextSeq 500 system also employs a novel two-channel sequencing strategy. In this approach, cytosine is labeled red, thymine is labeled green, adenine is effectively yellow (labeled with a mixture of red and green), and guanine is unlabeled. In contrast to the four-channel strategy used in the MiSeq and HiSeq platforms, two-channel sequencing requires only two images for nucleotide detection, reducing data processing times and increasing throughput. Despite the reduced complexity, the overall error rates (<1%) are similar to the more established HiSeq machines.
The HiSeq X Ten is a population-scale whole-genome sequencing (WGS) system that was also released in 2014. It is capable of outputting 1.8 Tb in 3 days or 18,000 genomes at 303 coverage per year. Currently, Illumina only supports WGS of human samples on HiSeq X Ten systems. In addition to enhanced optics and computing capacity, the HiSeq X Ten dramatically increases throughput by incorporating a new patterned flow cell technology that improves cluster generation chemistry. Patterned flow cells contain billions of nanowells that standardize cluster spacing and size, allowing higher cluster densities. Patterned flow cell technology is also used in the recently released HiSeq 3000/4000 machines, which provide outputs and run times in between the HiSeq X Ten and the HiSeq 2500.
Life Technologies/ThermoFisher/Ion Torrent Life Technologies commercialized Ion Torrent's semiconductor sequencing technology in 2010 in the form of the benchtop Ion PGM sequencer. The template preparation and sequencing steps are conceptually similar to the Roche/454 pyrosequencing platform (Margulies et al., 2005) . Namely, emulsion-PCR is used to clonally amplify adaptor-ligated DNA fragments on the surface of beads. The beads are subsequently distributed into microwells where a sequencing-by-synthesis reaction occurs (Ashton et al., 2015) . Numbers inside data points denote current read lengths. Sequencing platforms are color coded.
( Figure 2B ). Unlike pyrosequencing, which couples base incorporation with luciferase-based light production, Ion Torrent's semiconductor sequencing measures pH changes induced by the release of hydrogen ions during DNA extension (Rothberg et al., 2011) . These pH changes are detected by a sensor positioned at the bottom of the microwell and converted into a voltage signal. The voltage signal is proportional to the number of bases incorporated, and the sequential addition of individual nucleotides during each sequencing cycle allows base discrimination. Moreover, Ion Torrent avoids optical scanning to distinguish nucleotides during cycles of sequencing, a difference that dramatically speeds sequencing runs and reduces costs.
Ion Torrent released a second machine in 2012, the Ion Proton, which increases output over the PGM by an order of magnitude (1 Gb versus 10 Gb). However, the Proton currently features a maximum of 200 bp read lengths as opposed to 400 bp for the PGM. Multiple chips are also available to tailor outputs for different applications. The PGM is most useful for targeted resequencing projects and small genome analysis, whereas the Proton is capable of exome sequencing and whole-transcriptome analysis. The speed of sequencing, 2-8 hr depending on the machine and chip used, make these sequencers particularly useful for clinical applications (Mellmann et al., 2011) . Insertions and deletions (indels) are the most common error types . Because the correlation between the number of bases incorporated and the subsequent voltage change does not perfectly scale, homopolymer repeats longer than 6 bp lead to increased error rates (Rothberg et al., 2011) .
Pacific Biosciences
Single-molecule real-time (SMRT) sequencing was pioneered by Nanofluidics, Inc. and commercialized by Pacific Biosciences. Template preparation involves ligation of single-stranded, hairpin adapters onto the ends of digested DNA or cDNA molecules, generating a capped template (SMRT-bell). By using a strand displacing polymerase, the original DNA molecule can be sequenced multiple times, thereby increasing accuracy . Importantly, clonal amplification is avoided, allowing direct sequencing of native, and potentially modified, DNA. DNA synthesis occurs in zeptoliter-sized chambers, called zero-mode waveguides (ZMWs), in which a single polymerase is immobilized at the bottom of the chamber (Levene et al., 2003) ( Figure 3A) . The physics of these chambers reduces background noise such that phosphate-labeled versions of all four nucleotides can be present simultaneously. Thus, polymerization occurs continuously, and the DNA sequence can be read in real-time from the fluorescent signals recorded in a video (Eid et al., 2009) .
Released in 2010, the RS II remains Pacific Biosciences only commercially available machine. However, altering the chemistry and doubling the number of ZMWs to 150 k per SMRT cell have greatly enhanced performance. Using the latest chemistry, each SMRT cell produces 50 k reads and up to 1 Gb of data in 4 hr. The average read lengths are >14 kb, but individual reads can be as long 60 kb. As with most single-molecule sequencing platforms, high error rates (11%) are evident for single pass reads, and these errors are dominated by indels. Sequencing errors, however, are distributed randomly, allowing accurate consensus calls with increasing coverage or multiple passes around the same template, so-called circular consensus sequences (Carneiro et al., 2012; Koren et al., 2012) . By avoiding clonal amplification, SMRT sequencing is also much less sensitive to GC sequence content than other platforms (Loomis et al., 2013) . This suite of characteristics makes SMRT sequencing particularly useful for projects involving de novo assembly of small bacterial and viral genomes as well as large genome finishing (English et al., 2012) . Reconstructing structural variation (SV) in the genome (Chaisson et al., 2015) and isoform usage in the transcriptome (Sharon et al., 2013) are also key areas where SMRT sequencing has clear advantages over short read technologies. However, lower throughput and higher per base sequencing costs currently limit the scope of most genomewide studies. In addition to providing long, unbiased reads, another distinguishing characteristic of SMRT sequencing is that the polymerization reaction is monitored in realtime, allowing data pertaining to both base composition and enzymatic kinetics to be collected. Distinct kinetic profiles are produced as the polymerase encounters various types of DNA methylation . These kinetic signatures have been utilized to map sites of potential 6-methyladenine and 5-methylcytosine genome wide in bacteria (Fang et al., 2012) . It is possible that these approaches will be extended to map other types of DNA modifications, including DNA damage induced in cancer cells. Moreover, SMRT sequencing instruments are not limited to studying DNA alone, as other molecules, such as ribosomes, can be tethered to the bottom of the ZMW and monitored at single-molecule resolution (Uemura et al., 2010) .
Oxford Nanopore Technologies Nanopore-based sequencing is an emerging single-molecule strategy that has made significant progress in recent years, with Oxford Nanopore Technologies leading the development and commercialization of this method. Nanopore sequencing can take a variety of forms, but it principally relies on the transition of DNA or individual nucleotides through a small channel . In Oxford Nanopore's current technology, a sequencing flow cell comprises hundreds of independent micro-wells, each containing a synthetic bilayer perforated by biologic nanopores. Sequencing is accomplished by measuring characteristic changes in current that are induced as the bases are threaded through the pore by a molecular motor protein ( Figure 3B ). Library preparation is minimal, involving fragmentation of DNA and ligation of adapters. Much like SMRT sequencing, this library preparation methodology can be done with or without PCR amplification. The first adaptor is bound with a propriety motor enzyme as well as a molecular tether, whereas the second adaptor is a hairpin oligonucleotide that is bound by a second so-called HP motor protein (Quick et al., 2014) . This library design allows sequencing of both strands of DNA from a single molecule, which increases accuracy (Ashton et al., 2015; Quick et al., 2014) .
The first commercially available device for nanopore sequencing is the MinION, a USB-powered portable sequencer, which Oxford Nanopore Technologies released in early 2014 as part of an early access program. A single 18 hr run can produce >90 Mb of data from around 16,000 total reads, with median and maximum read lengths of 6 kb and >60 kb, respectively (Ashton et al., 2015) . As with all single-molecule sequencing methodologies, error rates are high. Jain and colleagues most recently reported insertion, deletion, and substitution rates of 4.9%, 7.8%, and 5.1%, respectively (Jain et al., 2015) . Presently, it also has a very high run failure rate. Despite the high error rates, MinION reads have been successfully used to determine the position and structure of a bacterial resistance island in combination with Illumina-derived reads (Ashton et al., 2015) and resolve an assembly gap on human Xq24 (Jain et al., 2015) . Given the relatively high error rates and low throughput, nanopore sequencing is unlikely to overtake current sequencing platforms in the near future; however, the combination of size, speed, read lengths, and machine cost hold promise for the future.
The Development and Use of HTS Applications
As sequencing costs have fallen, HTS machines have become widely present in university core facilities and even individual labs. Decreasing costs and increased accessibility have enabled researchers to develop a rich catalog of HTS applications ( Figure 4 ; Table 1 ). Some of these technologies were initially developed using DNA microarrays, but many are enabled only by using sequencing. HTS offers many advantages over DNA microarrays. In particular, it is more precise and not subject to cross-hybridization, thereby providing higher accuracy and a larger dynamic range (>10 5 for DNA sequencing versus 10 2 for DNA microarrays) (Wang et al., 2009) . Similar to microarrays, however, HTS-based applications can be biased by a number of variables, such as sequencing platform and library preparation method. The Sequencing Quality Control Consortium and similar initiatives are designed to study these biases and develop approaches to control for them, as has been recently demonstrated for RNA-seq (Su et al., 2014) . As HTS-based applications have become more robust, they have not only enabled individual researchers but also a variety of consortia-based projects. These large-scale projects have both provided valuable resources to the community and also have addressed questions that would be difficult for individual labs to approach. Some of these projects are listed in Table 2 and include efforts to characterize the human genome (ENCODE, Roadmap Epigenomics Project, 2015) , study human genetic variation (The 1000 Genomes Project Consortium, 2010), analyze gene expression (GTEx), and discover the molecular underpinnings of human disease (many; see Table 2 ). These coordinated efforts produce foundational resources that are of high utility to the scientific community by depositing the data into easily accessible public databases. Moreover, consortia often implement robust experimental and computational standards (e.g., Landt et al., 2012) , ensuring high-quality data. Use of HTS applications by both individual laboratories and the large consortia have enabled researchers to illuminate previously intractable topics in biology, some of which are discussed below.
Genome Sequencing and Variation
The utility of HTS technologies for determining genome sequences de novo was first demonstrated by sequencing the genome of Acinetobacter baumannii (Smith et al., 2007) . As the technologies and throughput improved, they were applied to ''resequencing'' human genomes and exomes, which was accomplished by first mapping reads to a reference genome and then identifying variants that differ between the sample genome and the reference (Wheeler et al., 2008) . The different genome sequencing projects have since revealed that individuals typically harbor 3.5-4 million single nucleotide variants (SNVs) in total and several hundred thousand short indels relative to the reference genome. Importantly, these variants include hundreds of loss of function alterations in genes (The 1000 Genomes Project Consortium, 2010).
HTS has also been used to globally characterize SV in the human genome. SVs include large (>1 kb) segments of the genome that have been duplicated, deleted, or rearranged. The short read lengths of most HTS platforms make determining SVs and indels more challenging than SNVs (Snyder et al., 2010) . Typically, at least four independent approaches are utilized to identify SVs in a genome. These approaches include depth of read coverage , mapping of paired end reads that are discordant from the reference genome (Korbel et al., 2007) , identifying split reads , and mapping of breakpoint junctions (Kidd et al., 2010) . Although each method has shortcomings, the improvement in resolution over array-based approaches has greatly enhanced our understanding of the prevalence of SVs throughout the genome and their contribution to disease. However, because no method or combination of them is comprehensive, SVs are never characterized in their entirety, if at all, in most sequencing projects.
In addition to identifying variants, it is also useful to assign them to paternal and maternal alleles, or ''phase'' them. Similar to SVs, current read lengths hinder our ability to phase genomes. This limitation can be circumvented by several methods, including sequencing parents, sequencing proximity ligated fragments , or dilution and barcoding strategies during template preparation to allow long read assembly (Kuleshov Voskoboynik et al., 2013) . With approximately 30 Gb of additional sequence data, 99% of the SNVs identified in a 503 genome can be phased into blocks that are 0.2-1 Mb in length (Kuleshov et al., 2014) . Understanding the phase of variants can have important clinical implications when determining if multiple damaging variants affect both copies of a gene or only one copy. To date, HTS has been applied to many thousands of genomes and many tens of thousands of exomes, yielding tremendous insight into human diversity and disease. Mapping Regulatory Information of the Genome HTS has applications beyond simply sequencing genomes. Perhaps one of the highest impact areas is the genome-wide mapping of DNA regulatory elements at high resolution. The first of these technologies was ChIP-seq in which DNA associated with a transcription factor (TF) or chromatin modification is immuno-selected and then sequenced using HTS (Johnson et al., 2007) . Mapping the sequences back to the genome reveals the location of bound regions or chromatin modifications. A more general method for discovering many putative regulatory regions is to map ''open'' regions of the genome using DNase I digestion, followed by DNA sequencing of the ends of the fragments (Crawford et al., 2006) . This method identifies approximately 50% of regions that are TF-bound as measured by ChIP-seq (Cheng et al., 2014) . DNase-seq, however, is quickly being replaced by Assay for Transposon Accessible Chromatin-seq (ATAC-seq) in which transposon-based insertion is used to map open chromatin regions with approximately 50 million mapped reads (Buenrostro et al., 2013) . The ATAC-seq protocol is also simpler and can be applied to small numbers of cells, even single cells.
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Regulatory information is especially revealing when compared across many individual genomes or within a single genome across many cell or tissue types. Large-scale application of these methods by the ENCODE project has provided a wealth of invaluable information regarding TF binding networks (ENCODE Project Consortium, 2012), epigenetic maps (Thurman et al., 2012) , and transcript annotations (Djebali et al., 2012) . Moreover, recent studies have found more than 3.5 million regulatory elements located throughout the genome in different cell types. One of the most striking findings from these studies as a whole, however, was the higher than expected portion of the genome that appears to be functional. The exact percentage is a source of significant debate (Doolittle, 2013) , highlighting the importance of further experimental evidence to assign function to genomic elements. Genome targeting techniques, such as CRISPR-Cas9 (Gilbert et al., 2014) as well as high-throughput enhancer assays (Kheradpour et al., 2013) , provide researchers with new tools to interrogate putative regulatory elements. Nonetheless, a variety of lines of evidence (GWAS and ENCODE) suggest that the total amount of regulatory regions is likely greater than that of protein coding regions (Kellis et al., 2014) . Mapping the 3D Organization of the Genome Our understanding of the global organization and compartmentalization of chromosomes has been profoundly advanced by HTS technologies. 3D chromatin interactions can be studied using a variety of HTS assays, such as chromatin interaction analysis by paired-end tag sequencing (ChIA-PET) and Hi-C (Fullwood et al., 2009; Lieberman-Aiden et al., 2009) . Each of these assays relies upon proximity-based ligation of cross-linked, sheared chromatin followed by sequencing to derive contact maps. Hi-C was the first technique to allow unbiased, genomewide interrogation of chromatin organization and revealed that the genome broadly partitions into open and closed chromatin Chromatin interaction analysis by paired-end tag sequencing (ChIA-PET) Chromatin conformation Fullwood et al., 2009 Chromosome conformation capture carbon copy (5-C) Chromatin conformation Dostie et al., 2006 Chromatin isolation by RNA purification sequencing (ChIRP-seq) Genome localization Chu et al., 2011 Reduced representation bisulphite sequencing (RRBS-seq) Genome methylation Meissner et al., 2008 Bisulfite sequencing (BS-seq) Genome methylation Cokus et al., 2008 DNAse-seq Open chromatin Crawford et al., 2006 Assay for transposase-accessible chromatin using sequencing (ATAC-seq) Open chromatin Buenrostro et al., 2013 Parallel Analysis of RNA structure (PARS) RNA structure Kertesz et al., 2010 Structure-seq RNA structure Ding et al., 2014 RNA on a massively parallel array (RNA-MaP) RNA-protein interactions Buenrostro et al., 2014 RNA immunoprecipitation sequencing (RIP-seq) RNA-protein interactions Sephton et al., 2011 Parallel analysis of RNA ends sequencing (PARE-seq) microRNA target discovery German et al., 2008 Massively parallel functional dissection sequencing (MPFD) Enhancer assay Patwardhan et al., 2012 Molecular Cell 58, May 21, 2015 ª2015 Elsevier Inc. 591
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Review states (Lieberman-Aiden et al., 2009) . Hi-C also demonstrated that the genome is organized into topological associating domains (TADs), which show high amounts of intra-domain interactions but exhibit infrequent interactions across domain boundaries (Dixon et al., 2012) . Interestingly, TAD organization is stable across cell types and evolutionarily conserved across species. The boundaries between TADs were also enriched for housekeeping genes and binding sites for the insulator protein CTCF, raising the possibility that the distribution of TADs is chromosomally encoded (Dixon et al., 2012) . Recent advancements to the Hi-C technique combined with extremely deep sequencing (billions of reads per sample) have produced much higher resolution contact maps (1 kb), which refine TAD domain size from 1 Mb to less than 200 kb (Rao et al., 2014) . These new Hi-C maps demonstrated intra-chromosomal looping events, often containing promoter-to-enhancer contacts that were associated with gene activation. Most loops were anchored with directionally oriented CTCF binding sites, suggesting a mechanistic role for CTCF in establishing stable loops. Strikingly, fewer than 10,000 looping events were observed genome wide, which is far smaller than previous estimates (Jin et al., 2013) . Modeling of Hi-C data has also suggested a fractal globule chromatin state, a conformation that both maximizes packing while preserving the flexibility to access any genomic locus (Lieberman-Aiden et al., 2009 ).
Characterizing the Transcriptome
Our appreciation for the diverse cellular roles of RNA has been greatly enhanced by the advent of HTS. Much of this evolution in thought has been a direct result of the many HTS applications designed to systematically identify various classes of RNA as well as to characterize RNA structure, RNA-protein interactions, and genomic localization. Cap analysis of gene expression (CAGE) and RNA-seq have been utilized to great effect to deeply characterize transcriptomes, providing precise, comprehensive measurements for message abundance, isoform usage, RNA-editing, and allele-specific expression. Deep sequencing of RNA has suggested that roughly three-quarters of the human genome is transcribed (Djebali et al., 2012) . Most of this transcription covers introns or is very low, non-coding and of unclear biologic significance. However, many interesting species of non-coding RNA, including long non-coding RNAs (lncRNAs), small nucleolar RNAs (snoRNAs), and microRNAs, have been systematically described with RNA-seq and derivative techniques. A subset of lncRNAs, for example, have been revealed by overlaying RNA-seq data with ChIPseq profiles characteristic of expressed genes . Building upon earlier cDNA sequencing and tiling array experiments, these HTS approaches expanded the list to include more than a thousand mammalian lncRNAs. Analogous expansions have occurred for many aspects of RNA biology, Exploring the challenges and opportunities associated with using genomic sequence information in the newborn period.
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www.niagads.org/adsp such as the number of sites undergoing RNA editing (Li et al., 2009) . Understanding the structure and biology of these newly discovered transcripts has led to the development of additional HTS applications. For instance, microRNA-target discovery has been facilitated by sequencing signatures of miRNA-mediated mRNA decay, using parallel analysis of RNA ends (PAREs) (German et al., 2008) . Furthermore, RNA immunoprecipitation chip (RIPchip) and subsequently RIP-seq were utilized to show that approximately 20% of the lncRNAs associate with polycomb repressor complex 2 (PRC2), a chromatin-modifying complex (Khalil et al., 2009; Zhao et al., 2010) . Given these links to chromatin, methods analogous to ChIP-seq were developed, such as chromatin isolation by RNA purification (ChIRP-seq), to determine the genomic localization of lncRNAs (Chu et al., 2011) . HTS applications have also made it possible to determine transcript structure both in vitro (parallel analysis of RNA sequencing; PARS) and in vivo (Structure-seq), providing insight into the effects of various structural features on translation efficiency, splicing, and polyadenylation (Ding et al., 2014; Kertesz et al., 2010) . More recently, systematic interrogation of sequence-function relationships for RNA-protein interactions has been made possible using a highthroughput biochemical assay called RNA on a massively parallel array (RNA-MaP) (Buenrostro et al., 2014) . The use of these assays, and many others, have enabled researchers to study RNA biology both comprehensively and with great detail, thereby enhancing our appreciation for the varied roles RNA plays in normal cellular homeostasis as well as human disease. Microbiome Sequencing Advances in HTS have enabled extensive cataloging of metagenomic samples, providing insight into the diversity of microbial species from a wide variety of sources, including the ocean, soil, and human body. These studies use both 16S rRNA gene sequencing to determine phylogenetic relationships as well as more comprehensive shotgun sequencing to predict detailed species and gene composition. In particular, much attention has been paid to characterizing the diverse microbes resident to healthy human populations (Human Microbiome Project Consortium, 2012 ). These studies found extensive variation in both body site habitat and among different individuals, giving rise to the concept of a ''personal microbiome.'' Microbial diversity, or the number and abundance distribution of microorganisms in a given niche, also correlates with several human diseases. For instance, an increase in diversity is associated with bacterial vaginosis (Fredricks et al., 2005) , whereas obesity and inflammatory bowel disease exhibit a decrease in the diversity of gut microbes (Qin et al., 2010; Turnbaugh et al., 2009) . Although transplant studies in mice have demonstrated a direct link between the gut microbiome, energy metabolism, and obesity (Turnbaugh et al., 2006) , causal relationships for the majority of human diseases are not well established. A deeper understanding will require more detailed characterizations of the dynamics of microbiomes across health states as well as more integrative studies to investigate the functional interplay between the microbiota, the host, and the environment.
Genome Sequencing of Rare Diseases
The capacity to sequence genomes, exomes, and transcriptomes has profoundly influenced our understanding of the genetics of human disease, especially for rare Mendelian disorders and cancer. According to the Online Mendelian Inheritance in Man database, there are more than 7800 Mendelian disorders, but the causative gene for less than one half of these are known. By sequencing unrelated patients or affected and unaffected family members, early exome studies demonstrated the ability to identify causal alleles for a variety of inherited diseases (Bilgü -var et al., 2010; Ng et al., 2010) . In rare cases, sequencing of patient samples has suggested specific clinical interventions that have dramatically altered patient outlook. In one early example, exome sequencing of a child with severe inflammatory bowel disease uncovered a mutation in an important regulator of inflammation, X-lined inhibitor of apoptosis (XIAP). Based on the severity of the child's symptoms as well as the molecular diagnosis, a bone marrow transplant was given to the patient, which subsequently alleviated his symptoms (Worthey et al., 2011) . Despite the power of HTS for disease gene discovery, however, exome sequencing currently identifies the genetic defect in only 25% of cases (Yang et al., 2013) . Cancer Genome Sequencing Cancer is another important arena where HTS has been applied to great effect. The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) have performed genome and exome sequencing on thousands of tumor-normal pairs. These studies have described the mutational landscapes for over 20 cancer types, demonstrating that tumors can vary dramatically in both the type and quantity of mutations (Lawrence et al., 2014) . These global descriptions have been integral to the development of background mutation rates that are necessary for the detection of cancer driver genes. For example, replication timing and gene expression were both found to be important covariates when determining if a gene is mutated at a rate higher than expected. Using these background models, TCGA-led projects discovered several novel cancer drivers, known drivers in new cancer types, and commonly disrupted pathways (Lawrence et al., 2014) . Moreover, WGS of cancer samples has also identified high-frequency, non-coding mutations, such as activating mutations in the TERT promoter (Huang et al., 2013) , a poorly characterized but highly relevant class of somatic variants.
The scale and sensitivity of HTS has also enabled global descriptions of tumor heterogeneity, clonal evolution, and the mechanisms underlying drug resistance. By tracking copy number aberrations in primary breast cancer cells using single-cell sequencing techniques, Navin and colleagues demonstrated that copy number rearrangements can occur in bursts, followed by persistent clonal expansion (Navin et al., 2011) . Point mutations, in contrast, appear to accumulate more slowly over time, giving rise to more extensive clonal diversity, which may enable the tumor to adapt to diverse selective pressures . In addition to examining clonal diversity, HTS has also been used to compare primary tumors with relapse lesions, allowing characterization of the effects of chemotherapy as well as the molecular mechanisms underlying resistance to therapy (Van Allen et al., 2014; Ding et al., 2012) . Together, these molecular portraits of cancer are forming the foundation of new paradigms for the diagnosis and treatment of cancer. (Ross et al., 2013) . In addition, the short read lengths produced by most current platforms severely limit our ability to accurately characterize large repeat regions, many indels, and SV, leaving significant portions of the genome opaque or inaccurate (Snyder et al., 2010) . The establishment of a gold standard genome, as envisioned by the Genome in a Bottle Consortium (Zook and Salit, 2011) as well as standards for data processing, variant calling, and reporting as set out in the CLARITY Challenge (Brownstein et al., 2014) , will be valuable for comparing and reporting the accuracy of different platforms and studies. Given the limitations and biases of different platforms, it is also likely that accurate genome sequencing will use a combination of technologies.
In addition to genomes, quantitative analysis of complete transcriptomes, with individual allelic and spliced isoforms, is hindered by short reads. Improvements in the throughput and accuracy of current long-read technologies, such as Pacific Biosciences and Oxford Nanopore Technologies, as well as the use of ''synthetic long-read methods'' in which longer fragments can be sequenced and assembled from short reads will help overcome these limitations (Tilgner et al., 2015) . Although both the research and medical communities are pressing forward with current technologies, these limitations will also continue to drive the innovation of new sequencing platforms (reviewed by Schadt et al., 2010) .
HTS in the Coming Era of Personalized Medicine
To date, clinical HTS has most often been employed on focused regions of the genome or in the context of small pathogen identification. For instance, prenatal tests designed to non-invasively detect chromosomal abnormalities in cell-free DNA from maternal blood are clinically available (e.g., Ariosa Diagnostics' Harmony Test and BGI's NIFTY Test). Similarly, targeted HTS of clinically actionable mutations is being utilized to guide the diagnosis and treatment of cancer (e.g., Foundation Medicine's FoundationONE test). HTS has also been employed in clinical contexts to monitor pathogen outbreaks, such as methicillinresistant S. aureus infections (Kö ser et al., 2012) . The development and use of these focused assays will continue to expand, but the full promise of personalized medicine relies upon the routine clinical application of more comprehensive techniques, such as WGS, which still faces significant challenges.
In order for large-scale genomics to become fully integrated into the clinic, we need to reduce the costs and timescales associated with storage and interpretation of genome data. Most importantly, however, we must improve our ability to understand the biological and clinical consequences of variants of unknown significance. This class of alterations is the most common in personal genome sequences and includes novel variants that affect the coding sequence of known disease-causing genes but can also refer to variants in genes previously unlinked to disease or in regulatory regions of the genome. Interpretation of these variants will benefit from additional genome sequencing as well as the data provided by large-scale genomics projects, such as ENCODE and GTEx, which enable the generation of more complete reference databases. Open access projects, such as the Personal Genomes Project and integrative Personal Omics Profiling (iPOP), will also provide valuable community resources for linking phenotypes to sequences (Chen et al., 2012; Church, 2005) . The incorporation of high-throughput biochemical measurements of novel variation and detailed health records along with open data sharing will maximize our ability to both interpret personal genomes and better understand human health and disease.
